



DEPARTMENT OF HEALTH & HUMAN SERVICES

HFI-35

6/3/98

Public Health Service

d1813b

MAY 19 1998

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

WARNING LETTER

Ref:OC:I1-1785

via fax: 011 886 2 2466228  
718 830 0344

President  
CFT Group  
Code Flier Technology Co., Ltd.  
4F-1 No. 168 Lien Cheng Rd.  
Chung Ho City  
Taipei, Taiwan  
R.O.C.

President  
CFT Corp.  
63-88 Wetherole Street 1F  
Rego Park, New York 11374

Dear Presidents:

This letter is written to advise you of items of noncompliance with the United States Federal regulations applicable to laser products. This notification results from a field test of the CFT laser data collector by Ms. Serrah Namini of the United States Food and Drug Administration Pacific Regional Staff at IDEXPO in Los Angeles on December 4, 1997.

1. 21 CFR 1010.2 and 1010.3. The laser product failed to be certified and identified as required by these regulations.
2. 21 CFR 1040.10. This laser product fails to comply with the applicable performance, labeling and informational requirements of the United States Federal Performance Standard for Laser Products.

Section 538(a) of the Federal Food, Drug, and Cosmetic Act (the Act), Chapter V, Subchapter C (formerly the Radiation Control for Health and Safety Act of 1968) prohibits any manufacturer from certifying or introducing into commerce laser products which do not comply with the standard. This section also prohibits any manufacturer from failure to establish and maintain required records or to submit required reports. Failure to respond to this letter may be considered to be a violation of paragraph 538(a)(4) of the Act. The Food and Drug Administration (FDA) is prepared to invoke regulatory actions if you fail to comply with these requirements. These actions may include an injunction and/or imposition of civil penalties as provided for in Section 539. Persons failing to correct violations and/or continued violations of the Act are

subject to civil penalties of up to \$1,000 per violation and up to a maximum penalty of \$300,000 without further notification by the FDA. In cases where a foreign manufacturer fails to respond, penalties may be imposed upon importers.

You must respond in writing within 15 days of receipt of this letter to one of the options listed below. In your response you must also provide the number of the referenced products which have been produced and the number of such products that have left the place of manufacture. In addition, if the product distribution was confined to specific geographical areas of the United States, please specify those areas.

1. Refutation - You may submit your views and evidence to establish that the alleged failures to comply do not exist.
2. Exemption Request - You may request an exemption from user and dealer/distributor notification and from obligation to correct the violative products. Your request must include the grounds upon which such exemption is requested (see 21 CFR 1003.30 and 1003.31).
3. Purchaser Notification and Corrective Action - If you neither refute the noncompliance nor request an exemption, then you must: (a) notify purchasers and dealers/distributors of the violative products as specified in 21 CFR 1003.10(b), and (b) submit a written corrective action plan (CAP) to fulfill your obligation under 21 CFR 1004.1 to repair, replace, or refund the cost of the violative products.
  - a. Notification Letter - Requirements for preparation of notification letters are prescribed in 21 CFR 1003.21 and 1003.22. A copy of the notification letter(s) sent to purchasers and dealers must also be sent to the FDA. It is recommended that you submit a draft of this letter to us for review.
  - b. Corrective Action Plan - Instructions for preparation of a CAP may be found in 21 CFR 1004.2, 1004.3, or 1004.4.

If you request additional time to prepare your refutation, notification, CAP, or evidence to support a requested exemption, you must provide the reasons for any delays and a reasonable target date for the full submission of your response. Be aware that if an acceptable CAP cannot be prepared promptly, you may be required to proceed with interim

notification to affected persons as required by 21 CFR 1003.11(c) and 1003.21. Therefore, you are encouraged to immediately begin your preparation of accurate user location lists.

The following failures to comply with the regulations regarding reports and record keeping and imports were observed:

1. 21 CFR 1002.10. According to our records, a product report has not been received for laser products manufactured by your company.
2. 21 CFR 1005.25. There is no designation of a permanent resident agent in the United States for Code Flier Technology Co. Ltd., in Taiwan.

Based on the above, the CDRH declares that Code Flier Technology Co. Ltd., has failed to conduct a testing program which ensures compliance with the applicable performance standard. The CDRH therefore, under authority of 21 CFR 1010.2(c), disapproves the testing and quality control program for your laser products.

This disapproval means that your firm is prohibited by Sections 534(h) and 538 of the Act from:

1. certifying the electronic products manufactured under the disapproved testing program,
2. introducing or importing products into the United States (U.S.) commerce which bear false and misleading certification, that is, products certified under the testing program which has been disapproved, and
3. introducing or importing into the U.S. commerce any product which does not have the certification label permanently affixed to the product, as required by 21 CFR 1010.2.

Under Section 536(a) of the Act, the CDRH is required to refuse entry or importation into the U. S. commerce of any electronic product if it appears that the product fails to comply with the applicable standards, or the manufacturer's testing program has been disapproved.

To resolve this matter, you must submit all the information required under 21 CFR 1002.10 such that the CDRH can determine that your company is in compliance with the Act, that the subject products comply with the performance standard, and that the testing program is in accord with good manufacturing practices.


**The CDRH will advise you whether your submittal is satisfactory.**

Your response should be sent to: Director, Division of Enforcement III (HFZ-340), Office of Compliance, Center for Devices and Radiological

Page 4 - President, CFT Group

Health, 2098 Gaither Road, Rockville, Maryland 20850. You are also requested to send a copy of your response to: Director, Compliance Branch, New York District Office, Food and Drug Administration, 850 Third Avenue, Brooklyn, NY 11232-1593. If you have further questions on these requirements, please contact the Electronic Products Branch at (301) 594-4654.

Sincerely yours,

A handwritten signature in cursive script, appearing to read "Lillian J. Gill".

Lillian J. Gill  
Director  
Office of Compliance  
Center for Devices and  
Radiological Health